Literature DB >> 975617

The elimination of phenytoin in man.

M J Eadie, J H Tyrer, F Bochner, W D Hooper.   

Abstract

1. Plasma phenytoin (diphenylhydantoin) levels after different drug doses were correlated with urinary 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) excretions in four subjects. 2. In three of four subjects the proportion of the phenytoin dose that was excreted as p-HPPH. In the fourth, p-HPPH output remained proportionate to dose of phenytoin until elimination of the drug fell below its input. 3. Plasma p-HPPH levels were measured in two subjects; the data suggested that the renal excretion of p-HPPH was not rate-limited. 4. In three of four subjects, there was the possibility that alternative pathways for eliminating phenytoin may have developed as drug doses increased and the capacity for forming p-HPPH became saturated. 5. Overall phenytoin elimination appeared to approach saturation at concentrations of the drug encountered therapeutically. When Michaelis-Menten kinetics were applied to data for phenytoin elimination in twenty-one adults and fifteen children, the mean apparent Km value for the adults corresponded to a plasma drug concentration of 5-8 mug/ml, and in the children to 5-3 mug/ml. The mean Vmax values in the two groups were, respectively 8-1 mg/kg per day and 12-5 mg/kg per day.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 975617     DOI: 10.1111/j.1440-1681.1976.tb02667.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  12 in total

1.  A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics.

Authors:  Clare Gaynor; Adrian Dunne; Cian Costello; John Davis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-16       Impact factor: 2.745

2.  Application of a simplified method to determine bioavailability of an oral dose of phenytoin.

Authors:  A L Davis; E J Begg; M C Kennedy; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

3.  Rate of phenytoin accumulation in man: a simulation study.

Authors:  T M Ludden; J P Allen; L W Schneider; S A Stavchansky
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

4.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

6.  Phenytoin elimination kinetics in two children with drug intoxication.

Authors:  K Abe; M Okano; H Sasaki
Journal:  Eur J Pediatr       Date:  1980-10       Impact factor: 3.183

7.  Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.

Authors:  L A Bauer; R A Blouin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

8.  Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.

Authors:  B Rambeck; H E Boenigk; E Stenzel
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

Review 10.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.